Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ONO-7475 + gemcitabine + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Ono Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
ONO-7475 + gemcitabine + nab-paclitaxel is an investigational drug combination for the treatment of metastatic pancreatic cancer evaluated in Phase 1 trials. - **ONO-7475** is a small molecule inhibitor of the receptor tyrosine kinases AXL and MERTK, implicated in cancer cell survival, proliferation, metastasis, and drug resistance. - **Gemcitabine** is a nucleoside analog antineoplastic that interferes with DNA synthesis by inhibiting DNA polymerase and ribonucleotide reductase, leading to cell death. - **Nab-paclitaxel** (paclitaxel albumin-bound, commercial name Abraxane) is a microtubule stabilizer that impairs cell division by binding to tubulin, leading to mitotic arrest and apoptosis. This triple-combination aims to potentiate antitumor efficacy by: targeting survival and resistance pathways (AXL/MERTK inhibition), and enhancing cytotoxicity via chemotherapy (gemcitabine and nab-paclitaxel). Its use is studied as a first-line regimen in metastatic pancreatic cancer[2][6].
- Other names
- gemcitabinepaclitaxel albumin-boundONO-7475 + gemcitabine + nab-paclitaxel
02
Targets
AXL (AXL receptor tyrosine kinase)RNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))DNA polymerase familyMERTK (MER proto-oncogene, tyrosine kinase)
Beyond the preview
Go deeper on ONO-7475 + gemcitabine + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ONO-7475 + gemcitabine + nab-paclitaxel.